- 4basebio
- 02 April 2025 10:49:16
Source: Sharecast
The AIM-traded firm said the certification, granted under a Manufacturer’s and Importation Authorisation (MIA), permitted it to manufacture and supply both Investigational Medicinal Product drug substances and critical starting materials used in the production of Advanced Therapy Medicinal Products.
It said the capabilities would position the company to support clinical development efforts and future commercialisation in the field of advanced therapeutics.
4basebio develops synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform.
The firm said the approval demonstrated its ability to meet stringent regulatory standards for the production of DNA materials intended for clinical use, and supported its broader strategy to enable next-generation genetic therapies.
“Achieving GMP certification is a critical milestone for 4basebio, validates our ability to supply synthetic DNA for clinical applications and underscores the hard work and innovation of our team and sets the stage for the next phase of growth for the company,” said chief executive officer Heikki Lanckriet.
At 1001 GMT, shares in 4basebio were up 3% at 1,200p.
Reporting by Josh White for Sharecast.com.
